Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 23348503)

1.

TERT promoter mutations in familial and sporadic melanoma.

Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R.

Science. 2013 Feb 22;339(6122):959-61. doi: 10.1126/science.1230062. Epub 2013 Jan 24.

2.

Highly recurrent TERT promoter mutations in human melanoma.

Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA.

Science. 2013 Feb 22;339(6122):957-9. doi: 10.1126/science.1229259. Epub 2013 Jan 24.

3.

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17426-31. doi: 10.1073/pnas.1310522110. Epub 2013 Oct 7.

4.

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R.

Nat Commun. 2014 Feb 26;5:3401. doi: 10.1038/ncomms4401.

PMID:
24569790
5.

TERT promoter mutation is uncommon in acral lentiginous melanoma.

Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW.

J Cutan Pathol. 2014 Jun;41(6):504-8. doi: 10.1111/cup.12323. Epub 2014 Apr 2.

PMID:
24588324
6.

TERT promoter mutations in cancer development.

Heidenreich B, Rachakonda PS, Hemminki K, Kumar R.

Curr Opin Genet Dev. 2014 Feb;24:30-7. doi: 10.1016/j.gde.2013.11.005. Epub 2013 Dec 20. Review.

PMID:
24657534
7.

[Tert promoter mutations in melanoma: not only the MAP-kinase pathway].

Dereure O.

Ann Dermatol Venereol. 2013 Jun-Jul;140(6-7):487-8. doi: 10.1016/j.annder.2013.04.071. Epub 2013 May 15. French. No abstract available.

PMID:
23773757
8.

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D.

J Natl Cancer Inst. 2014 Sep 13;106(9). pii: dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep.

PMID:
25217772
10.

EWS/ETS fusions activate telomerase in Ewing's tumors.

Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, Ohno T, Taira T, Ariga H, Nakajima K, Hatta M, Kobayashi M, Sano H, Kohgo T, Shindoh M.

Cancer Res. 2003 Dec 1;63(23):8338-44.

11.

Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J.

J Natl Cancer Inst. 2003 Jun 4;95(11):790-8.

12.

Ets-1/Elk-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells.

Shukla AA, Jain M, Chauhan SS.

FEBS J. 2010 Apr;277(8):1861-75. doi: 10.1111/j.1742-4658.2010.07603.x. Epub 2010 Mar 2.

PMID:
20236318
13.

TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.

Griewank KG, Murali R, Schilling B, Schimming T, Möller I, Moll I, Schwamborn M, Sucker A, Zimmer L, Schadendorf D, Hillen U.

PLoS One. 2013 Nov 18;8(11):e80354. doi: 10.1371/journal.pone.0080354. eCollection 2013.

14.

Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.

Braunstein I, Cohen-Barak O, Shachaf C, Ravel Y, Yalon-Hacohen M, Mills GB, Tzukerman M, Skorecki KL.

Cancer Res. 2001 Jul 15;61(14):5529-36.

15.
16.
17.

Characterization of the human insulin-induced gene 2 (INSIG2) promoter: the role of Ets-binding motifs.

Fernández-Alvarez A, Soledad Alvarez M, Cucarella C, Casado M.

J Biol Chem. 2010 Apr 16;285(16):11765-74. doi: 10.1074/jbc.M109.067447. Epub 2010 Feb 9.

18.

Characterization of the promoter for the alpha3 integrin gene in various tumor cell lines: roles of the Ets- and Sp-family of transcription factors.

Katabami K, Kato T, Sano R, Ogura M, Mizuno H, Itoh S, Tsuji T.

J Cell Biochem. 2006 Feb 15;97(3):530-43.

PMID:
16211576
19.

Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter.

Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J.

Genes Dev. 1996 Sep 1;10(17):2198-211.

20.

Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway.

Maida Y, Kyo S, Kanaya T, Wang Z, Yatabe N, Tanaka M, Nakamura M, Ohmichi M, Gotoh N, Murakami S, Inoue M.

Oncogene. 2002 Jun 13;21(26):4071-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk